UBS Maintains a Buy Rating on Harmony Biosciences Holdings (HRMY), Sets a $50 PT

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) is one of the best affordable biotech stocks to invest in now. On September 12, UBS analyst Ashwani Verma maintained a Buy rating on Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) and set a price target of $50.00.

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) reported its fiscal Q2 2025 results on August 5, with its WAKIX franchise continually delivering strong growth with net revenue of $200.5 million for the quarter, up 16% year-over-year.

The company also announced the initiation of next-generation Pitolisant HD Phase 3 registration trials in Narcolepsy & Idiopathic Hypersomnia in Q4 2025, with both indications targeted for PDUFA in 2028.

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) is a commercial-stage pharmaceutical company that develops and commercializes therapies to treat neurological disorders.

Its product, WAKIX, is a molecule that increases histamine signaling in the brain by binding to H3 receptors. The company has one of the strongest pipelines for people with rare neurological diseases.

While we acknowledge the potential of HRMY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.